Literature DB >> 10872671

Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.

P Korkolopoulou1, P Christodoulou, A E Konstantinidou, E Thomas-Tsagli, P Kapralos, P Davaris.   

Abstract

Cyclin-dependent kinase inhibitors (CKIs) prevent cyclin-dependent kinases from phosphorylating critical substrates such as retinoblastoma gene protein (pRb), hence blocking the cascade of events leading to cell proliferation. Currently, the list of CKIs includes p21WAF1/Cip1, p27Kip1, p57Kip2 (the Cip/Kip family), p15/ INK4b, p16/INK4a, p18/INK4c, and p19/INK4d (the INK4 family). Among them, p27 plays a crucial role linking extracellular growth-regulatory signals to progression to or exit from the cell cycle. Unlike p53, p16, and Rb, mutations in Kip1 and WAF1 genes are distinctly rare in bladder cancer. We analyzed immunohistochemically the expression of p27 and other interacting G1 proteins (ie, p21, p16, pRb, p53) in 120 consecutive cases of transitional cell carcinomas (TCCs) and related it to proliferation rate, clinicopathologic parameters, and survival. p27 levels were significantly higher in low-grade (P = .001), superficial (Ta-T1) (P = .001), papillary (P < .001), and slowly proliferating TCCs (rs = -0.235, P = .05). p27 also positively correlated with p16 expression (rs = 0.212, P = .05). In univariate analysis, decreased p27 expression was associated with poor overall (P = .0109) and postrelapse (P = .0344) survival, especially if combined to increased Ki-67 expression (P = .0004 and P = .036, respectively). Furthermore, in multivariate analysis, Ki-67/p27 status had the strongest bearing on the overall survival of muscle-invasive TCCs (P = .0019). Our results indicate that low p27 expression is more common in poorly differentiated muscle-invasive TCCs and is a major player in cell cycle control in these neoplasms. More importantly, the combined Ki-67/p27 expression provides prognostic information beyond that provided by conventional parameters or other cell cycle-related proteins, concerning overall survival in muscle-invasive TCCs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10872671     DOI: 10.1053/hupa.2000.8227

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Transcriptional and post-transcriptional upregulation of p27 mediates growth inhibition of isorhapontigenin (ISO) on human bladder cancer cells.

Authors:  Guosong Jiang; Chao Huang; Jingxia Li; Haishan Huang; Jingjing Wang; Yawei Li; Fei Xie; Honglei Jin; Junlan Zhu; Chuanshu Huang
Journal:  Carcinogenesis       Date:  2018-03-08       Impact factor: 4.944

3.  Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Authors:  Said Akli; Xin-Qiao Zhang; Jolanta Bondaruk; Susan L Tucker; P Bogdan Czerniak; William F Benedict; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

4.  DNAse I pre-treatment markedly enhances detection of nuclear cyclin-dependent kinase inhibitor p57Kip2 and BrdU double immunostaining in embryonic rat brain.

Authors:  Weizhen Ye; Georges Mairet-Coello; Emanuel DiCicco-Bloom
Journal:  Histochem Cell Biol       Date:  2006-10-06       Impact factor: 4.304

5.  P27(Kip1) and Ki-67 expression analysis in transitional cell carcinoma of the bladder.

Authors:  Bartosz Dybowski; Jolanta Kupryjańczyk; Alina Rembiszewska; Roman Pykało; Andrzej Borkowski
Journal:  Urol Res       Date:  2003-09-27

6.  Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?

Authors:  Latife Doganay; Semsi Altaner; Selcuk Bilgi; Esat Kaya; Galip Ekuklu; Kemal Kutlu
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

7.  Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.

Authors:  Adam S Feldman; Jacqueline Banyard; Chin-Lee Wu; W Scott McDougal; Bruce R Zetter
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 9.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.